Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

We are now offering COVID-19 vaccine appointment scheduling at our Walk-In Center at 292 Long Ridge Road. Please remember, masks are required in all Stamford Health facilities and you may be asked to provide proof of vaccination.

$345 Million Settlement Proposed in EpiPen Lawsuits

FRIDAY, July 16, 2021 (HealthDay News) -- Pfizer Inc. has agreed to pay $345 million in a proposed settlement to resolve lawsuits over steep EpiPen price increases.

EpiPens are auto-injectable devices that deliver the drug epinephrine for emergency treatment of a life-threatening allergic reaction called anaphylaxis.

In 2016, a number of class-action lawsuits were filed against Pfizer and its subsidiaries Meridian Medical Technologies Inc. and King Pharmaceuticals, alleging they engaged in anticompetitive conduct related to EpiPen, the Associated Press reported.

Another company that is a defendant in the litigation is Mylan, which owns the EpiPen brand, even though the devices are made by Pfizer.

Mylan acquired the right to market and distribute the devices in 2007, when an EpiPen package cost about $100. Now, it costs more than $650 without pharmacy coupons or manufacturer discounts, the AP reported.

Court documents filed Thursday in federal court in Kansas City, Kansas, show that Pfizer and its two subsidiaries asked the court to give preliminary approval to the settlement, according to Kansas City's NPR station KCUR-FM.

Three weeks ago, most of the claims against Mylan were dismissed, but the judge allowed antitrust claims against the company to proceed to trial, scheduled to start on Sept. 7, the AP reported.

Rex Sharp, a lawyer for the plaintiffs, said his clients were pleased that Pfizer had agreed to the settlement, noting it would still need the court's approval, the AP reported

In an email to KCUR-FM, a Pfizer spokesperson denied any wrongdoing by the company and said the settlement was sought to avoid "the distraction of continued litigation and focus on breakthroughs that change patients' lives."

More information

The National Institute of Allergy and Infectious Diseases has more on food allergies.


SOURCE: Associated Press


Copyright ©2021 HealthDay. All rights reserved.

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.